A hospice-first, evidence-based clinical reference for clinicians, families, and patients navigating this diagnosis at end of life. Built for the team beside the bed.
Definition, mechanism, and the clinical reality of progressive supranuclear palsy at end of life. What the hospice team needs to understand on day one.
Progressive supranuclear palsy (PSP) is a relentless, tau-mediated neurodegenerative disease that systematically dismantles the motor, communication, and eye movement systems while often leaving the patient's cognitive awareness largely intact. PSP belongs to the family of 4-repeat tauopathies — diseases in which the microtubule-associated protein tau misfolds, hyperphosphorylates, and aggregates into neurofibrillary tangles that kill neurons in specific, predictable brain regions. In PSP, those regions include the subthalamic nucleus, the globus pallidus, the superior colliculus, the pedunculopontine nucleus (PPN), the periaqueductal gray, and the frontal cortex. The selective destruction of these structures produces PSP's signature clinical combination: vertical gaze palsy (loss of voluntary downward eye movement), postural instability with sudden backward falls, axial rigidity, bulbar dysfunction (dysarthria and dysphagia), and frontal lobe cognitive-behavioral changes — all progressing on a timeline that is among the most compressed in neurodegenerative medicine.[1][5]
The hospice clinician who receives a PSP patient inherits a clinical situation defined by five parallel crises converging simultaneously: (1) the communication crisis — dysarthria that has progressed from slurred speech to near-unintelligibility, with a window for augmentative and alternative communication (AAC) introduction that closes without warning; (2) the fall crisis — sudden, backward, reflexless falls that cannot be prevented by environmental modification alone because they arise from PPN neurodegeneration rather than from external hazards; (3) the swallowing crisis — neurogenic dysphagia progressing faster than in almost any other neurodegenerative disease except bulbar-predominant ALS, with aspiration pneumonia as the most likely cause of death; (4) the gaze crisis — loss of voluntary downward gaze that removes the patient's ability to make normal eye contact, to read, to see their food, to see the ground, producing a specific form of relational isolation; and (5) the identity crisis — a patient who is often alert, oriented, and cognitively aware, trapped inside a failing motor system that has silenced their voice, frozen their gaze, and eliminated their ability to move safely through the world.[6][7]
The most clinically important fact about PSP at hospice enrollment is the misdiagnosis history. The typical PSP patient spent 2–4 years being treated for Parkinson's disease. The levodopa didn't work — or worked minimally. The falls kept happening backward. The eyes began doing something the family couldn't explain. Eventually, a movement disorder specialist said the words: Progressive Supranuclear Palsy — a disease the family had never heard of, with a prognosis fundamentally different from the Parkinson's trajectory they had prepared for. The recalibration that PSP demands of the family — from "Parkinson's, decades of gradual decline" to "PSP, years of rapid, relentless loss" — is one of the most demanding prognostic reframes in all of neurology. The hospice clinician who asks, "Can you tell me what the journey to this diagnosis was like?" receives the emotional context that no medical record captures.[2][8]
Every visit to a PSP patient must assess five domains that are simultaneously active and simultaneously progressing: (1) Communication — has speech intelligibility declined since last visit? Is the AAC system in place and being used? Has the voice banking window closed? (2) Falls — have new falls occurred? Were there injuries? Is the helmet being worn? Is the bed at lowest height? Are crash mats in place? (3) Swallowing — are there new signs of aspiration (wet voice, cough with liquids, recurrent pneumonia)? Has the dietary texture been updated? Is the aspiration pneumonia advance directive documented? (4) Eye movement — has the gaze limitation worsened? Is the family positioning themselves in the patient's functional gaze field? Are communication devices positioned at or above resting gaze? (5) Dignity — is the patient receiving care that acknowledges the alert, aware person inside the failing body? Is drooling being managed? Is the patient being spoken to directly, not through the caregiver?
Diagnostic criteria, neurological examination findings, and what to look for in hospice records. The PSP diagnosis is clinical — this section helps you read it, document it, and explain it.
The Movement Disorder Society (MDS) 2017 diagnostic criteria replaced the NINDS-SPSP criteria as the standard for PSP classification:[9]
At hospice enrollment: Document the clinical variant (PSP-RS, PSP-P, other); the year of symptom onset; the year of correct PSP diagnosis; the duration of the Parkinson's misdiagnosis period; whether levodopa was trialed and the response; and whether the characteristic MRI hummingbird sign was present.[9]
One of the most distinctive features of PSP is the loss of voluntary downward eye movement. The nerve connections that normally allow the brain to send "look down" instructions to the eyes are damaged by the disease. The eyes can still move normally when the head is moved passively — but the voluntary "look down" command cannot reach them. This is why your person may have difficulty looking at their food on a plate, reading a book in their lap, seeing where they are stepping, or making eye contact when you are sitting beside them. It is not that they do not want to look at you. It is that the disease has taken away the brain pathway that allows that movement. You can help by sitting at or above their natural eye level, positioning materials at eye level or above, and understanding that when they tilt their head backward, they may be trying to use gravity to redirect their gaze. The loss of eye contact is one of the most painful aspects of this disease for families — and knowing that it is the disease, not a choice, matters.[11]
PSP pathogenesis, the tau biology, why PSP falls are different from all other falls, and answering the family's question: "Why did this happen?"
The features that distinguish PSP from idiopathic Parkinson's disease (IPD) — and that were eventually recognized during the misdiagnosis period:
PSP is not caused by anything your loved one did or did not do. It is not caused by diet, lifestyle, stress, head injuries, or environmental exposures. PSP occurs when a specific protein in the brain (tau) begins to fold incorrectly and accumulate in brain cells that control eye movement, balance, speech, and swallowing. Scientists do not yet understand what triggers this process. There is a small genetic variation that slightly increases susceptibility, but PSP is not a hereditary disease that passes directly from parent to child — the risk to other family members is not meaningfully elevated above the general population. The research community is actively working on treatments that target the tau protein, but no therapy yet exists that can slow or stop the disease. What we can do is manage every symptom aggressively, preserve communication as long as possible, reduce injury from falls, and ensure that your person's comfort and dignity are protected at every stage.[14][15]
Unlike some neurodegenerative diseases (Huntington's, familial ALS, BRCA-associated cancers), PSP does not warrant routine genetic counseling for family members. The MAPT H1 haplotype is a population-level risk factor present in the majority of the general population — it is not a deterministic mutation. Families who ask about genetic risk can be reassured that PSP is an overwhelmingly sporadic disease and that the probability of another family member developing PSP is not meaningfully different from the general population risk. The exception: if there is a family history of multiple members with parkinsonism, frontotemporal dementia, or corticobasal syndrome, a referral to a genetics specialist may be appropriate to evaluate for rare MAPT mutations (which are associated with frontotemporal dementia with parkinsonism linked to chromosome 17, FTDP-17, rather than sporadic PSP).[14]
PSP symptom management — the comprehensive comfort framework. There is no disease-modifying therapy. Every intervention is directed at comfort, safety, communication preservation, and dignity.
There is no disease-modifying therapy for PSP. No medication slows, stops, or reverses the tau aggregation that drives the disease. The entire treatment framework in PSP is symptomatic and supportive — and the hospice clinician who understands this can redirect every clinical decision through a single lens: does this intervention reduce suffering or preserve function that matters to this patient? The five treatment domains in PSP hospice care are: fall safety management, communication preservation (AAC and voice banking), swallowing management and aspiration prevention, retrocollis and pain management, and sialorrhea (drooling) management. Each domain has specific interventions, specific timing urgencies, and specific advance directive implications.[6][15]
The most important clinical distinction in PSP fall management is between fall prevention (reducing fall frequency — possible but incomplete) and fall injury prevention (reducing injury severity — the more achievable goal):[16]
The most time-sensitive clinical act in PSP hospice care. The AAC window closes without warning.[20]
In PSP there is no disease-directed therapy — but there are specific symptomatic and supportive interventions whose timing is critical. "When therapy makes sense" in PSP means: when the intervention still has a window.
In oncology, "when therapy makes sense" refers to disease-directed treatment. In PSP, there is no disease-directed treatment. The equivalent question is: when does a specific supportive intervention still have a window of effectiveness — and what must the hospice team do at enrollment to ensure that window is not missed? The time-sensitive interventions in PSP are not medications — they are communication acts, equipment decisions, environmental modifications, and advance directive conversations. Every one of them has a specific window that closes, and the closure is often irreversible.[6]
Interventions that do not help — and may harm — in progressive supranuclear palsy. Knowing when to stop is not clinical failure. It is the most important clinical skill in this disease.
PSP hospice care involves a specific set of deprescribing decisions and intervention withdrawals that require evidence-based justification. The medications and interventions that were appropriately tried during the diagnostic phase — when the working diagnosis was Parkinson's disease — must be reassessed now that the correct diagnosis is known. The general principle is the single comfort-benefit question: Is this medication or intervention producing documented comfort or functional benefit in this patient right now? If the answer is no, it is adding pill burden, side effect risk, and cost without clinical justification.[31]
The PSP patient at hospice enrollment typically arrives on a medication regimen designed for Parkinson's disease — a disease they do not have. The deprescribing conversation at enrollment is specific and compassionate: "When your person was diagnosed with Parkinson's disease, these medications made sense for that diagnosis. Now that we know the diagnosis is PSP — a different disease with different brain chemistry — some of these medications are no longer helping and may be causing side effects that make things harder. I'd like to go through each one with you and keep only the ones that are providing real comfort." Review every medication through the single comfort-benefit question. Taper levodopa (do not stop abruptly). Discontinue dopamine agonists. Replace CNS-penetrating anticholinergics with peripheral alternatives. Add glycopyrrolate for sialorrhea, acetaminophen for pain, and melatonin for sleep disruption. The goal is a medication list that serves the real disease, not the former misdiagnosis.[31][32]
Evidence-graded integrative, interventional, and adaptive approaches for PSP. Grade A = RCT-level; B = multi-observational/meta-analysis; C = limited clinical, strong rationale; D = expert opinion/case series.
The most urgent and most commonly missed intervention in PSP. Voice banking records the patient's natural speaking voice while any intelligible speech remains. The recordings capture the full phonemic inventory of the language and are compiled into a personalized synthetic voice profile. This voice is then programmed into the patient's AAC device — so that when they use text-to-speech, their own voice speaks their words, not a generic computer voice.[22]
Because PSP falls are predominantly backward, conventional gait assistance (walking beside or behind the patient) positions the caregiver on the wrong side of the fall vector. The backward-walking technique positions the caregiver directly in the path of the most likely fall direction:[18]
Standard front-wheeled walkers position the patient's center of gravity forward, which partially counteracts the backward lean of PSP. However, they require the patient to reach forward — a posture that the axial rigidity and retrocollis of PSP resist. Posterior-weighted or reverse-configured walkers offer an alternative:[18]
Botulinum toxin injection to the salivary glands is the most effective intervention for sialorrhea refractory to oral anticholinergics. The evidence base includes Cochrane-reviewed RCTs (primarily in ALS, stroke, and Parkinson's disease) with strong efficacy signals:[34]
The frontal lobe apathy of PSP produces emotional blunting and social withdrawal that standard pharmacotherapy addresses poorly. Music therapy offers a non-pharmacological pathway to emotional engagement:[35]
Prism glasses attempt to redirect the visual field downward by bending light, partially compensating for the loss of voluntary downgaze:[36]
Evidence grading, dosing where supported, drug interaction flags, and explicit contraindications specific to PSP physiology. Patients and families will seek supplements — this section helps you have the right conversation.
Progressive supranuclear palsy creates a supplement safety landscape defined by two concerns unique to PSP physiology: (1) Frontal lobe cognitive changes produce specific sensitivity to CNS-acting supplements — any supplement with sedating properties may cause disproportionate cognitive slowing that further impairs the communication capacity already severely compromised by bradyphrenia and dysarthria. Any supplement that adds to cognitive slowing is specifically harmful in a disease whose primary communication barrier is the slowing of thought processing. (2) Sialorrhea management — any supplement with salivary-stimulating properties (pilocarpine-containing preparations, high-dose vitamin C) will worsen the drooling that is already one of the most distressing symptoms of PSP. The supplement evaluation in PSP should ask: Does this supplement worsen cognitive slowing (avoid)? Does this supplement stimulate salivation (avoid)? Does this supplement interact with the anticholinergic medications used for sialorrhea? Does this supplement provide documented comfort benefit for any specific PSP symptom? The family seeking something to "help the brain" deserves an honest answer: no supplement has been shown to alter the tau pathology of PSP in human trials.[37]
| Herb / Supplement | Evidence Grade | Typical Dose | Potential Benefit | ⚠ Interactions / Contraindications |
|---|---|---|---|---|
| Melatonin | Grade C | 3–5 mg at bedtime | Sleep disruption in PSP — from retrocollis pain, REM sleep behavior disorder, altered sleep-wake cycle from frontal lobe disease. No significant drug interactions with PSP comfort medications. Favorable safety profile in elderly.[38] | Minimal risk. May cause morning drowsiness — monitor next-day communication quality. No interaction with glycopyrrolate, acetaminophen, or low-dose opioids. PSP-safe: does not worsen cognitive slowing at standard doses; does not stimulate salivation. |
| Coenzyme Q10 (CoQ10) | Grade D | 300–1,200 mg daily in divided doses | Mitochondrial support. Studied in PSP — the QE3 trial (a large multicenter RCT) tested CoQ10 in PSP and found no clinical benefit at 2,400 mg/day. The trial was stopped for futility. The supplement is safe but does not alter PSP progression.[39] | No significant drug interactions. Well tolerated. PSP note: Families may have read about CoQ10 for neurodegeneration — communicate the PSP-specific trial result directly: "This was tested specifically in PSP and did not help." Costly at high doses. |
| Omega-3 Fatty Acids (Fish Oil) | Grade C | 1–2 g EPA+DHA daily | Anti-inflammatory properties. No PSP-specific evidence, but general evidence for anti-inflammatory and neuroprotective effects in neurodegenerative disease populations. May support mood in patients with frontal lobe apathy.[40] | Mild antiplatelet effect — monitor if patient is on anticoagulants or has fall-related bleeding risk (relevant in PSP). GI upset at high doses. PSP note: Liquid formulations may present aspiration risk in patients with severe dysphagia — use capsule form only if patient can safely swallow capsules. |
| Vitamin D3 | Grade C | 1,000–2,000 IU daily | PSP patients are at extreme risk for vitamin D deficiency due to immobility, limited sun exposure, and reduced oral intake. Vitamin D supplementation supports bone density — relevant because PSP falls produce fractures at high rates. Also emerging evidence for vitamin D's role in neuroinflammation reduction.[41] | No significant interactions. Well tolerated. Check 25-OH vitamin D level if not done recently. PSP note: One of the few supplements with clear clinical rationale specific to PSP — the combination of immobility + frequent high-impact falls = high fracture risk = vitamin D supplementation justified. |
| Turmeric / Curcumin | Grade D | 500–1,000 mg curcuminoid extract daily | Anti-inflammatory and anti-amyloid properties demonstrated in preclinical models. No human clinical evidence of benefit in PSP or any tauopathy. Families commonly seek this as a "brain supplement."[37] | Poor oral bioavailability (mitigated partially by piperine-containing formulations). CYP3A4/CYP2C9 inhibitor — potential interaction with medications metabolized by these pathways. GI upset. Antiplatelet effect at high doses. PSP note: No harm at standard doses, but no expected benefit. Allow continued use if family finds comfort in it; redirect expectations from "helping the brain" to "no proven benefit but no significant harm." |
| Magnesium Glycinate | Grade C | 200–400 mg elemental magnesium at bedtime | Muscle relaxant properties may help with the axial rigidity and dystonia of PSP. Sleep support. Constipation relief (common in PSP from immobility and anticholinergic medications).[42] | Glycinate form preferred for better tolerability and lower GI effect than citrate or oxide. Monitor for loose stools. Avoid in renal impairment (GFR <30). PSP note: Reasonable adjunctive for rigidity, constipation, and sleep — three common PSP symptoms. Does not worsen cognitive slowing; does not stimulate salivation. |
A guide, not a prediction. The PSP trajectory is shaped by the clinical variant, the timing of diagnosis, the aspiration pneumonia that is the leading cause of death, and the specific sequence of disability that distinguishes PSP from all other neurodegenerative diseases.
The PSP timeline is characterized by two features that distinguish it from other neurodegenerative diseases: the compressed total trajectory (5–9 years from symptom onset in PSP-Richardson syndrome, with 2–4 years consumed by the Parkinson's misdiagnosis) and the specific sequence of disability — falls and gaze palsy first, then dysarthria and dysphagia, then complete loss of speech and mobility, then immobility and aspiration pneumonia as the terminal event. The hospice team typically enters at the transition between the middle and late stages — when falls have produced serious injuries, speech is significantly impaired, and swallowing has become unsafe. The timeline below is organized by the phases the patient and family have experienced and will experience. PSP-Parkinsonism (PSP-P) follows a similar sequence but on a longer timeline (8–12 years total); PSP-RS progresses on the compressed timeline described here.[3][6]
Symptom-targeted pharmacology for PSP at hospice enrollment. Deprescribing the Parkinson's medications that aren't helping, and initiating the comfort medications that will.
PSP medication management at hospice enrollment requires the same deprescribing approach as geriatric frailty applied to the PSP-specific context. The levodopa that was prescribed for Parkinson's disease and that provides minimal or no benefit in PSP should be reassessed and likely discontinued — the potential risk of levodopa withdrawal (dopamine supersensitivity reaction) requires taper, not abrupt cessation; do not stop levodopa abruptly but do taper over 1–2 weeks and reassess.[41] The dopamine agonists (pramipexole, ropinirole) that provide even less benefit than levodopa in PSP and that carry significant side effect burden (hallucinations, somnolence, compulsive behaviors, orthostatic hypotension) should be stopped.[42]
Beyond deprescribing: the PSP comfort medication plan addresses the five most prevalent symptom burdens: sialorrhea (anticholinergic agents); retrocollis neck pain (acetaminophen, low-dose opioid, botulinum toxin referral); dysphagia (dietary modification, postural techniques — pharmacological management is limited); sleep disruption (melatonin); pain and dystonia (acetaminophen, low-dose opioid).[43]
The single most important pharmacological safety concern in PSP: any CNS-depressant medication that worsens cognitive slowing reduces the communication capacity that AAC depends on — use the lowest effective dose of any sedating medication and monitor communication quality after any new sedating medication is initiated.[38]
| Drug | Class / Target Symptom | Starting Dose | Notes / Cautions |
|---|---|---|---|
| Glycopyrrolate | Anticholinergic / Sialorrhea (drooling) | 1–2 mg PO TID | Preferred anticholinergic for PSP sialorrhea. Quaternary ammonium compound — minimal CNS penetration, does not cross the blood-brain barrier well, and therefore does not worsen the bradyphrenia and frontal lobe dysfunction of PSP.[33] Same anticholinergic mechanism as central agents (benztropine, trihexyphenidyl) but without cognitive side effects. Start at 1 mg TID; titrate to 2 mg TID as tolerated. Monitor for constipation, urinary retention, dry mouth (therapeutic for sialorrhea but may impair oral comfort if excessive). ⚠ Caution: do not substitute with benztropine or trihexyphenidyl — central anticholinergics worsen PSP cognitive slowing. |
| Scopolamine patch | Anticholinergic / Sialorrhea (alternative) | 1.5 mg patch q72h | Transdermal scopolamine as alternative or adjunct for sialorrhea. Applied behind the ear; change every 72 hours. Some CNS penetration — monitor for confusion, visual hallucinations, and increased cognitive slowing.[34] More convenient than oral glycopyrrolate for patients with severe dysphagia who cannot reliably swallow tablets. ⚠ Caution: higher CNS side effect risk than glycopyrrolate. Use glycopyrrolate first if oral route available. |
| Atropine 1% drops (sublingual) | Anticholinergic / Sialorrhea (acute) | 1–2 drops SL q4–6h PRN | Atropine ophthalmic 1% solution used sublingually for acute sialorrhea episodes. Rapid onset (15–30 minutes). Short duration of action. Useful as PRN rescue medication when glycopyrrolate is not controlling breakthrough drooling episodes.[35] Minimal systemic absorption from sublingual route. Teach family to administer. Keep in comfort kit. PRN for social situations, mealtimes, or breakthrough drooling. |
| Botulinum toxin (salivary gland injection) | Neurotoxin / Sialorrhea (refractory) | 30–50 units per parotid gland; 10–15 units per submandibular | For sialorrhea refractory to oral anticholinergics. Requires specialist referral (movement disorder neurologist, ENT, or physiatrist). Effect lasts 3–4 months. Ultrasound guidance improves accuracy.[36] Can be combined with botulinum toxin for retrocollis if administered by the same specialist at the same session. ⚠ Caution: small risk of worsening dysphagia — weigh against sialorrhea severity. |
| Acetaminophen | Analgesic / Retrocollis neck pain, general comfort | 650–1000 mg PO q6h (max 3 g/day) | First-line analgesic for the chronic neck pain caused by retrocollis and axial dystonia. Schedule around the clock — not PRN — for continuous retrocollis pain. Reduces opioid requirement. No CNS depression, no worsening of bradyphrenia, no impact on communication capacity.[39] Use liquid formulation if dysphagia impairs tablet swallowing. Reduce maximum to 2 g/day if hepatic impairment or low body weight. |
| Morphine | Opioid / Pain, dystonia pain, dyspnea | 2.5–5 mg PO/SQ q4h PRN; ATC if pain continuous | For retrocollis pain not controlled by acetaminophen alone; for dystonic spasm pain; for dyspnea in advanced PSP. Use the lowest effective dose — all opioids worsen cognitive slowing and may impair communication capacity.[43] Monitor communication quality after initiation. Liquid morphine concentrate (20 mg/mL) preferred for advanced dysphagia. ⚠ Caution: start low, assess communication impact before titrating. Add bowel regimen on day one. |
| Botulinum toxin (cervical injection) | Neurotoxin / Retrocollis, cervical dystonia | 100–300 units divided across posterior cervical muscles | For retrocollis causing significant pain, functional impairment, or airway compromise. Requires referral to movement disorder neurologist or physiatrist. Effect lasts approximately 3 months; may be repeated.[37] Reduces cervical extensor spasm and the associated pain. Can be combined with soft cervical collar. ⚠ Caution: risk of neck weakness, transient worsening of dysphagia. Discuss with patient and family before proceeding. |
| Baclofen | Muscle relaxant / Axial rigidity, dystonia | 5 mg PO TID; titrate to 10–20 mg TID | For generalized axial rigidity and limb dystonia not responsive to botulinum toxin. GABAergic mechanism provides some relief of spasticity component. Start low, titrate slowly.[40] ⚠ Caution: CNS depression — may worsen cognitive slowing and impair communication capacity. Do not discontinue abruptly (seizure and withdrawal risk). Monitor communication quality at each dose increase. |
| Melatonin | Sleep regulator / Sleep disruption | 3–5 mg PO at bedtime | Sleep disruption in PSP results from multiple mechanisms: retrocollis pain affecting positioning, REM sleep behavior disorder from brainstem degeneration, altered sleep-wake cycle from frontal lobe disease. Melatonin has no significant CNS depression, no cognitive side effects, no impact on communication capacity.[43] Preferred over benzodiazepines and sedative-hypnotics as first-line sleep agent. May increase to 10 mg if no response at 5 mg. |
| Mirtazapine | Antidepressant / Depression, insomnia, weight loss | 7.5–15 mg PO QHS | First-line antidepressant for PSP patients with comorbid depression, insomnia, and/or weight loss. Addresses three symptom burdens simultaneously. Sedating at lower doses (7.5 mg) — use this therapeutically for insomnia. Appetite stimulation beneficial for patients with weight loss from dysphagia-related decreased intake.[51] ⚠ Caution: sedation may worsen bradyphrenia at higher doses. Monitor communication quality. |
| Lorazepam | Benzodiazepine / Anxiety, acute distress | 0.5 mg PO/SL/SQ q6h PRN | For anxiety episodes, acute emotional distress, and dyspnea-associated anxiety. Use PRN, not scheduled — benzodiazepines worsen cognitive slowing and communication capacity in PSP.[43] Sublingual formulation useful for patients with severe dysphagia. ⚠ Caution: falls risk amplified in PSP — benzodiazepine-induced sedation on top of existing postural instability. Use lowest effective dose. Reserve for genuine distress episodes. |
| Midazolam | Benzodiazepine / Terminal agitation, catastrophic symptoms | 2.5–5 mg SQ PRN; CSCI 10–30 mg/24h if refractory | For terminal agitation, refractory distress, and catastrophic symptom management in the final days. Pre-draw and label in comfort kit for after-hours use.[43] Family must be taught subcutaneous administration before the crisis. In PSP: aspiration events causing acute respiratory distress may require midazolam for symptom relief. Have in comfort kit from enrollment. |
| Glycopyrrolate (injectable) | Anticholinergic / Terminal secretions | 0.2 mg SQ q4h PRN | For terminal secretions (death rattle) in the final days. Same pharmacological advantage as oral glycopyrrolate — no CNS effects, preferred over hyoscine/scopolamine in patients with residual consciousness.[33] Also useful for severe sialorrhea when oral route is no longer available. Include in comfort kit. |
| Haloperidol | Antipsychotic / Nausea, delirium, agitation | 0.5–1 mg PO/SQ q8h PRN | For nausea (opioid-induced or metabolic), delirium, and agitation in advanced PSP. Useful antiemetic when metoclopramide is contraindicated. ⚠ Caution: dopamine receptor blockade — theoretically could worsen parkinsonian features in PSP, though in practice the disease itself has already destroyed the dopaminergic pathways. Use lowest effective dose. Avoid in PSP patients with residual levodopa response.[43] |
| Levodopa/carbidopa (taper to discontinue) | Dopamine precursor / Deprescribing target | Taper by 100 mg levodopa/day every 3–5 days | Deprescribe — not continue. If the patient is on levodopa from the prior Parkinson's diagnosis and cannot demonstrate meaningful clinical benefit, taper and discontinue. Do NOT stop abruptly — dopamine supersensitivity reaction risk. Taper gradually over 1–2 weeks while monitoring for withdrawal symptoms (fever, rigidity, autonomic instability).[41] If any worsening during taper, resume at previous dose and taper more slowly. Document the deprescribing decision and rationale. |
The following medications must be pre-drawn, labeled, and at the bedside from enrollment — before the crisis, not during it:
The aspiration crisis: PSP patients die of aspiration pneumonia more often than any other cause. When the aspiration event happens — the acute choking, the coughing, the respiratory distress — the family must have the comfort medications at hand and the advance directive answers already documented. This is not a kit that can wait until the second visit.[27]
High-yield clinical pearls for the hospice team. The things not in the textbook — learned at the bedside with PSP patients over years of clinical experience.
The alert person inside the failing body. Gaze palsy as relational loss. Misdiagnosis grief. The symptom burden you cannot see on a vitals sheet — but that defines every visit in PSP.
Progressive supranuclear palsy produces a specific and profound form of existential suffering that is distinct from any other neurodegenerative disease. The PSP-Richardson syndrome patient is cognitively present — episodic memory relatively intact, orientation preserved, emotional awareness fully functional — while the motor system that enables communication, eye contact, mobility, feeding, and self-care is progressively and rapidly destroyed. The result is a person who is alert, oriented, and aware of everything happening around them, but who cannot speak, cannot make normal eye contact, cannot walk, cannot write, and who is wearing a bib to catch the drool that their bulbar muscles can no longer manage. This is not the late-stage Alzheimer's patient for whom cognitive awareness has faded alongside motor function. This is the person who is fully present inside the failure.[49]
The psychosocial care of PSP must begin with the explicit clinical acknowledgment of this specific suffering — and then address the unique dimensions of grief, loss, and relational disconnection that PSP imposes on the patient, the family, and the caregivers who watch it happen.[50]
PSP-Richardson syndrome preserves episodic memory and general orientation while destroying motor and communication function. The cognitive changes that do occur in PSP are frontal-executive in nature — slowed processing (bradyphrenia), executive dysfunction, impulsivity, and apathy — but these are qualitatively different from the memory loss of Alzheimer's disease.[55]
The hospice chaplain, social worker, or nurse who specifically acknowledges this reality — who says directly to the patient: "I want you to know that I see you — not the disease, not the wheelchair, not the communication board — the person who is in here and who is watching and understanding everything that is happening" — provides a recognition that the PSP patient may not have received from any other clinical encounter.[50]
Human connection is substantially mediated through eye contact. The PSP patient who cannot look downward cannot make normal eye contact with people sitting at a normal level without tilting their head backward in a posture that is both uncomfortable and strange-looking. The loss of normal eye contact is a loss of one of the most fundamental channels of human connection — the ability to look at the people you love, to read their facial expressions, to communicate care and recognition and presence through the eyes. The gaze palsy of PSP takes this away progressively, first in the vertical plane and eventually in the horizontal plane as well.[53]
The hospice chaplain who sits at a height that allows comfortable eye contact for the PSP patient — who adjusts their physical position to be in the patient's functional gaze field — is performing a clinical act of respect. Acknowledge the gaze palsy as a relational loss: "The inability to look at the people you love the way you used to must be its own grief — and I want you to know that the people who love you see past the eyes that don't move the way they used to. They see you."[50]
"Teach every family member, every aide, and every visitor: sit at or above the patient's eye level. Do not stand over them looking down — they cannot look up at you. Do not sit below them — they cannot look down at you. Position yourself where the eyes can reach you. This is not a convenience. This is how you maintain the human connection that PSP is trying to take away."
The median time from PSP symptom onset to correct PSP diagnosis is 2–4 years. During this period, the vast majority of patients are diagnosed with idiopathic Parkinson's disease and treated with levodopa that provides minimal or no benefit.[6]
The misdiagnosis grief must be named, validated, and addressed as a clinical entity — not left to simmer beneath the surface of every care conversation.
PSP caregiver burden is among the highest of any neurodegenerative disease. Studies consistently demonstrate that PSP caregivers report higher levels of distress, depression, and burden than caregivers of patients with Parkinson's disease or Alzheimer's disease.[49] The reasons are PSP-specific: the sudden, unpredictable, injury-producing falls that the caregiver witnesses and cannot prevent; the rapid loss of communication that eliminates the patient's ability to express needs, preferences, and love; the drooling that the caregiver must constantly manage; the feeding difficulties that transform every meal into an aspiration risk; the gaze palsy that takes away the eye contact that was the last reliable channel of emotional connection.
The PSP caregiver is not just watching a person decline — they are watching a person who is aware of their own decline and who cannot tell them how it feels. The empathic burden of this is enormous. Screen caregivers for depression, anxiety, and caregiver burnout at every visit. The PHQ-2 takes 30 seconds and should be directed at the caregiver as well as the patient.[51]
Depression affects 50–60% of PSP patients — significantly higher than the general hospice population.[51] Screening is complicated by the communication impairment: the patient who cannot speak cannot answer the PHQ-2 verbally. Adapt the screening:
Use the FICA framework (Faith/beliefs, Importance, Community, Address) adapted for PSP communication limitations. If the patient can still speak: ask directly. If the patient uses AAC: prepare yes/no spiritual assessment questions in advance. If the patient has no AAC: the chaplain's role shifts to presence, observation, and family-mediated spiritual history.[50]
Key spiritual questions for PSP: "What gives you strength during this time?" — opens the door. "Is there a faith community or spiritual leader who should know you're ill?" — identifies resources. "What do you most want your family to remember about you?" — both assessment and intervention. In PSP, legacy work may require AAC-facilitated recording of the patient's words, dictated letter writing, or video recording while communication is still possible.
Plain language for families living with PSP. Share, print, or read aloud at the bedside.
If you are reading this, someone you love has been diagnosed with progressive supranuclear palsy — PSP. You may have spent months or even years being told this was Parkinson's disease before you heard the name PSP. That experience — of preparing for one disease and then learning it is something different, something faster, something without the medications that Parkinson's patients rely on — is one of the hardest things about this journey. We want you to know: the grief of that correction is real, it is legitimate, and we are here to help you through it.
The most important thing to understand about PSP: your person is still in there. The disease takes away movement, speech, eye contact, and swallowing — but it does not take away awareness, understanding, or the ability to feel love. Your person hears you. Your person understands you. Your person needs you to keep talking to them, keep touching them, and keep treating them as the person they have always been.[49]
What to do after a fall: Stay calm. Stay with your person. Check: are they awake? Are they responding to your voice? Are they moving their arms and legs? Call the hospice nurse immediately after any fall that involves the head — even if your person seems fine. Some serious head injuries do not show symptoms immediately. Follow the advance directive guidance for emergency transport if any signs of confusion, severe headache, or unequal pupils appear.
Your person's eyes may not move the way they used to. PSP affects the nerve connections that allow the eyes to look up and down voluntarily. Your person may not be able to look down at a plate of food, look down at a book, or look down at someone sitting in a chair beside the bed. The eyes themselves are healthy — it is the brain's instructions to the eyes that have been damaged by the disease.
What this means for you: When you visit, sit at or slightly above your person's eye level. Do not sit in a low chair beside the bed — they cannot look down at you. Raise the chair, sit on the edge of the bed, or stand where their eyes can reach you. This small adjustment restores the eye contact that is one of the most important channels of love and connection between you. Your person's eyes may look different — wide, staring, less expressive — but the person behind those eyes is the same person who has always loved you.[53]
Many families of PSP patients spent months or years being told their person had Parkinson's disease before the name PSP was used. If this happened to you, we want you to know: this delay is common, it is not anyone's fault, and the grief you feel about it is completely normal. PSP looks like Parkinson's disease in its early stages — the slowness, the stiffness, the balance problems. The differences that eventually make the PSP diagnosis clear — the backward falls, the eye movement changes, the lack of response to Parkinson's medication — develop over time.
You are not alone. CurePSP (CurePSP.org) is the primary support organization for PSP patients and families. They offer support groups, educational materials, a helpline, and connections to other families who understand exactly what you are going through. Ask the hospice social worker to help you connect.[54]
After any fall: confusion, severe headache, unequal pupils, vomiting, inability to move an arm or leg, loss of consciousness — even briefly. During or after eating: choking that does not resolve with coughing, blue or gray color around the lips, sudden difficulty breathing, high fever (above 101°F) developing within 24–48 hours of a choking episode. Any time: sudden inability to swallow even liquids, new or worsening confusion, severe agitation or distress that comfort measures are not helping, breathing that sounds labored, wet, or significantly different from normal.
🙏 You are doing one of the hardest things a family can do — caring for a person whose body is failing while their mind is still aware. Your presence matters more than any medical intervention we provide. Research consistently shows that patients who have family present experience less pain, less anxiety, and more peace. You are not just watching — you are part of the treatment team. Your voice, your touch, and your presence are medications we cannot prescribe. When you feel overwhelmed, call us. We are here for you — not just for your person. You do not have to do this alone.
Clinical field wisdom from 12+ years at the bedside. The things you learn after doing this long enough. Not guidelines — real. PSP-specific.
Peer-reviewed citations organized by clinical category. Based on articles retrieved from PubMed. All PMIDs hyperlinked. Evidence levels assigned by study design.
terminal2.care content is for educational purposes and is not a substitute for clinical judgment. Based on articles retrieved from PubMed. © Terminal2 | terminal2.care
Session notes — not saved to any server. Clears when you close the tab.
Use this space for visit notes, clinical reminders, or patient-specific observations. This text is stored only in your browser session.